Full-Time
Director MarTech Product Excellence and Operations
Novartis
10,001+ employees
Global pharmaceutical company delivering science-based innovations
Compensation Overview
$185.5k - $344.5k/yr
Remote in USA + 1 more
More locations: East Hanover, NJ, USA
Hybrid
Remote employees may need periodic visits to East Hanover, with travel and lodging at their own expense; relocation is not provided.
Bachelor's, MBA
 Product (1) |
|---|
Get referred to Novartis
See people who can refer or advise you
- A bachelor's degree in business, engineering, or a related field is required.
- At least 8 years of experience in MarTech product management, product operations, or related disciplines is required, including expertise across product discovery, prioritization, delivery, and optimization.
- Demonstrated success advancing MarTech product management maturity through scalable operating models, governance frameworks, and best practices.
- Ability to lead complex, cross-functional initiatives and drive results in highly matrixed global organizations.
- Exceptional communication skills and strong executive presence, with a track record of influencing senior stakeholders and guiding strategic decisions without direct authority.
- Experience partnering with external consulting firms, vendors, and strategic partners to accelerate business outcomes.
- Expertise in portfolio management, investment prioritization, governance, and KPI development to measure product and organizational performance.
- Ability to apply an analytical and data-driven mindset to turn insights into actionable strategies that drive measurable business impact.
- Drive product management excellence across a complex MarTech portfolio through scalable operating models, governance, and best practices while partnering with senior leaders to shape strategy, influence decision-making, and foster cross-functional alignment in a highly matrixed environment.
- Shape and execute the product management maturity roadmap, advancing frameworks, standards, and ways of working across teams.
- Establish and measure KPIs, maturity metrics, and continuous improvement initiatives to enhance MarTech product performance and delivery outcomes.
- Champion best practices across MarTech product discovery, prioritization, development, launch, and performance measurement.
- Lead portfolio governance processes that enable clear prioritization, effective decision-making, and organizational accountability.
- Partner across MarTech Product, IT, Marketing, and business teams to align strategy, investments, and execution priorities.
- Develop executive-level dashboards, reporting, and insights that drive transparency and informed decision-making.
- Support annual and quarterly planning, budgeting, roadmap development, and portfolio optimization to maximize business impact and return on investment.
- Lead change and transformation initiatives, advancing AI-enabled capabilities, operational excellence, and a culture of continuous learning and innovation.
- An MBA or advanced degree is preferred.
- Brand analysis.
- Brand awareness.
- Commercial excellence.
- Cross-functional collaboration.
- Customer engagement.
- Customer insights.
- Digital marketing.
- Influencing skills.
- Inspirational leadership.
- Media campaigns.
- People management.
- Product marketing.
- Product roadmap development.
- Return on investment.
- Stakeholder engagement.
- Stakeholder management.
- Thought leadership.
- Trend analysis.
Novartis is a global pharmaceutical company that uses science-based innovations to develop treatments and improve patient outcomes worldwide. Its products are medicines developed through research and development to address various diseases, aiming to reach nearly 1 billion people. The company differentiates itself by large-scale investment in R&D, a global presence with a diverse workforce, and a clear mission to Reimagine Medicine, focusing on meeting the changing needs of patients. Its goal is to improve quality of life and extend life expectancy by delivering meaningful therapies through its research and development efforts.
Company Size
10,001+
Company Stage
IPO
Headquarters
Basel, Switzerland
Founded
1970
Get referred to Novartis
See people who can refer or advise you
Simplify's Take
What believers are saying
- Novartis reported Q2 2026 sales of $14.4 billion, up 3% year over year.
- Kisqali, Scemblix, Kesimpta, and Pluvicto drove growth in Q2 2026.
- UK High Court upheld Entresto patent validity on August 13, 2026, protecting cash flow.
What critics are saying
- Novartis recalled Diovan lot AV5913C on August 4, 2026 after dissolution failures.
- Entresto faces generic attacks; Accord planned a rival launch later in 2026.
- Novartis cut 792 New Jersey jobs in 2026, signaling restructuring pressure and execution strain.
What makes Novartis unique
- Novartis owns Entresto, Leqvio, Pluvicto, and Fabhalta across major disease franchises.
- Novartis scales radioligand therapy with five U.S. manufacturing sites by July 31, 2026.
- Novartis keeps converting late-stage science into approvals, including Fabhalta on July 17, 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Growth & Insights and Company News
6 month growth
↓ -4%1 year growth
↓ -4%2 year growth
↓ -4%FDA recalls blood pressure medications nationwide - here's how to check if yours is affected. 56 minutes ago The FDA has announced recalls involving commonly prescribed blood pressure medications, with thousands of bottles affected nationwide. If you take either of these medications, it's worth checking your bottle before taking your next dose. The U.S. Food and Drug Administration says chlorthalidone tablets are being recalled after the manufacturer found they had "failed dissolution specifications." Testing raised concerns that the tablets may not dissolve the way they are supposed to, potentially affecting how the medication is absorbed by the body. The recall involves 25-milligram chlorthalidone tablets distributed across the United States by Risiong Pharma Holdings, Inc. According to the FDA, abou 11,460 bottles are included in the recall. The affected products are: 100-count bottles: NDC 64980-599-01, batch RISA24001 1,000-count bottles: NDC 64980-599-10, batch RISB24002 Expiration date: 04/2027 Chlorthalidone is a commonly prescribed diuretic used to help control high blood pressure. It can also be prescribed to reduce fluid retention. If your bottle matches the recall information, don't simply stop taking the medication on your own. Contact your pharmacy or prescribing healthcare provider and ask about a replacement or another appropriate option. The FDA has not yet classified this particular recall by severity. Another blood pressure drug is also being recalled The FDA also reported that Novartis voluntarily initiated a recall of Diovan (valsartan) 160 mg on August 4. The recall was announced by the agency on August 8. Valsartan belongs to a class of medications known as angiotensin II receptor blockers, or ARBs. These drugs work by blocking a substance that causes blood vessels to tighten, helping lower blood pressure. Valsartan is also used to treat heart failure and certain patients following a heart attack. The Diovan recall involves: Medication: Diovan (valsartan) 160 mg Quantity: 90 tablets Lot: AV5913C Expiration: 06/2027 Prescription: Rx only The medication was manufactured by Patheon Manufacturing Services in North Carolina and distributed by Novartis from its New Jersey operation. Why were the tablets recalled? The FDA says the Diovan recall was also triggered by "failed dissolution specifications." That doesn't necessarily mean the medication is toxic or contaminated. Instead, the concern is that the tablets may not dissolve according to the specifications used to ensure the drug is properly absorbed. The FDA classified the Diovan recall as a Class II recall on August 7. That's the agency's middle-level recall category. It generally means exposure to the affected product could cause temporary or medically reversible health consequences, while the likelihood of a serious health problem is considered remote. What should you do if you take one of these medications? First, check the bottle rather than assuming your prescription is part of the recall. The specific lot and expiration information matters. If your medication matches one of the recalled products, contact the pharmacy that filled your prescription or your healthcare provider for instructions and a possible replacement. And as with any prescription medication recall, don't abruptly stop taking a blood pressure medication without speaking with a healthcare professional first. Suddenly stopping certain medications can create its own health risks. If you've already taken medication from an affected lot and are experiencing concerning symptoms, contact your healthcare provider promptly.
Kynexis pockets €97m to advance cognition-focused schizophrenia drug. The Novartis-backed biotech will now prepare for registrational studies on KYN-5356 in CIAS. Dutch biotech Kynexis has banked €97m ($113m) through an extended Series A funding round, which the company will use to support the mid-to-late-stage development efforts for its lead cognitive disorder asset KYN-5356. Backed by notable contributors like Novartis' venture arm and Forbion, Kynexis will use the funds to facilitate close-out activities for its US-based, proof-of-concept Phase II study of KYN-5356, which is currently evaluating the drug's adjunctive potential in cognitive impairment associated with schizophrenia (CIAS). Kynexis expects to report topline results from this trial, which has enrolled around 150 adults with CIAS across 13 clinical sites, by the end of 2026. Alongside the Phase II trial, the funding will also help Kynexis prepare for its planned registrational trial on KYN-5356 in CIAS, while exploring the drug's potential in other cognitive disorders such as Alzheimer's disease. Kynexis has developed its oral lead therapy, KYN-5356, as a potentially first-in-class option for CIAS - a disease which currently has no specifically approved treatment options. Designed as an inhibitor of a key brain enzyme, kynurenine aminotransferase II (KAT-II), Kynexis claims that the drug can restore the signalling balance to receptors in the brain that are responsible for learning, memory and executive function. While the estimated prevalence of CIAS amongst the schizophrenic patient population varies significantly, a recent paper published in Schizophrenia Research: Cognition estimates that cognitive impairment is present in around 80% of patients with the condition. According to a 2026 real-world analysis, many patients with schizophrenia also display signs of CIAS, though most remain undiagnosed. Reinvigorating the schizophrenia treatment landscape. With a large portion of schizophrenia patients impacted by cognitive impairment and no approved therapies that can address such an affliction, there is a clear unmet need for the condition. While Kynexis' drug could hold the potential to fulfil some significant unmet needs in this space, Bristol Myers Squibb (BMS)-owned Karuna's Cobenfy (xanomeline and trospium chloride) could also offer new hope for patients with CIAS, as a retrospective analysis of a Phase III trial previously revealed that patients taking the drug performed better on a cognitive test than those in the placebo group. Alongside this development, Orzyon Genomics is also conducting the Phase II EVOLUTION study (EUCT 2023-507372-42-00) on its selective LSD1 inhibitor, vafidemstat, for the treatment of CIAS. Meanwhile, Monument Therapeutics has also begun a Phase I/II study (NCT07226895) on its drug, MT-1988, in patients who are at high clinical risk of psychosis, which is looking at cognitive, clinical, biological and digital measures in patients after eight weeks of treatment. Give your business an edge with its leading industry insights.
Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies. * Late-breaking Phase IV VICTORION-CHALLENGE data will evaluate Leqvio(R)(inclisiran) vs. bempedoic acid in achieving LDL-C goals * New AZALEA-TIMI 71 analyses will further characterize the bleeding profile of abelacimab in patients with atrial fibrillation, including recurrent bleeding events * Lp(a)CCELERATE, in partnership with European Atherosclerosis Society (EAS), will explore strategies to help advance guideline-recommended Lp(a) testing in clinical practice Basel, August 19, 2026 - Novartis will present data from 10 abstracts across its cardiovascular portfolio at the 2026 European Society of Cardiology (ESC) Congress, reinforcing its leadership in addressing cardiovascular risk. "The data we are presenting at this year's ESC Congress underscore our commitment to advancing cardiovascular science for patients who remain at risk despite current treatment," said Ruchira Glaser, M.D., Global Head, Cardiovascular, Renal and Metabolic Development, Novartis. "From foundational medicines Leqvio and Entresto to promising investigational therapies, our portfolio reflects our focus on addressing persistent challenges in cardiovascular care." Key abstracts accepted by ESC include: | Medicine/Disease | / | Abstract Title | / | Presentation Details | | Leqvio(R) | / | Head-to-head comparison of inclisiran vs bempedoic acid for LDL C lowering in patients with high and very high cardiovascular risk: Results from the phase 4 VICTORION-CHALLENGE trial | / | Tripoli (Hall B1) Late-Breaking Oral Presentation August 31, 08:15-08:30 CEST | | Leqvio(R) | / | An inclisiran-based treatment strategy reduces the need for therapy escalation to achieve low-density lipoprotein cholesterol goals: Exploratory findings from the VICTORION-Difference trial | / | Exchange Circle 3 (Research Gateway - Hall A1) ePoster August 29, 09:15-10:00 CEST | | Abelacimab | / | Effect of abelacimab vs. rivaroxaban on total bleeding events in patients with atrial fibrillation: an analysis from AZALEA-TIMI71 | / | Science Box 2 (Research Gateway - Hall A1) Oral Presentation August 29, 09:30-10:30 CEST | | Lipoprotein (a) [Lp(a)] | / | Mobilizing core and country-tailored implementation strategies to accelerate Lipoprotein(a) testing across Europe: findings from the Lp(a)CCELERATE contextual analysis | / | Exchange Circle 6 (Research Gateway - Hall A1) ePoster August 29, 16:15-17:00 CEST | | Entresto(R) | / | Effects of sacubitril/valsartan versus enalapril on NT-proBNP and hs-troponin T in patients with heart failure due to Chagas disease: insights from the PARACHUTE-HF trial | / | Station 5 (Research Gateway - Hall A1) ePoster August 31, 09:15-10:00 CEST | | Pacibekitug | / | TRANQUILITY: Efficacy of monthly and quarterly dosing of pacibekitug (IL-6 ligand mAb) targeting inflammation in CKD with high cardiovascular risk | / | Munich (Main Auditorium-Hall B3) Hot Line August 29, 08:45-09:00 CEST | About Novartis in Cardiovascular Disease At Novartis, we're redefining cardiovascular care, shifting toward earlier action, expanding how we understand and treat cardiovascular disease, and pushing the boundaries of what's possible so more people can live longer, healthier lives. Building on our 40-year legacy, we're committed to shaping what's next in cardiovascular care through bold science and a diverse, industry-leading pipeline. Disclaimer This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements can generally be identified by words such as "potential," "can," "will," "plan," "may," "could," "would," "expect," "anticipate," "look forward," "believe," "committed," "investigational," "pipeline," "launch," or similar terms, or by express or implied discussions regarding potential marketing approvals, new indications or labeling for the investigational or approved products described in this press release, or regarding potential future revenues from such products. You should not place undue reliance on these statements. Such forward-looking statements are based on our current beliefs and expectations regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that the investigational or approved products described in this press release will be submitted or approved for sale or for any additional indications or labeling in any market, or at any particular time. Nor can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise. About Novartis Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 300 million people worldwide. Reimagine medicine with us: Visit us at https://www.novartis.com and connect with us on LinkedIn, Facebook, X/Twitter and Instagram. Novartis Media Relations E-mail: [email protected] Novartis Investor Relations Central investor relations line: +41 61 324 7944 E-mail: [email protected]
Novartis defeats UK court bid to invalidate blockbuster drug Entresto patent. By Thomson Reuters Aug 13, 2026 | 8:56 AM LONDON, Aug 13 (Reuters) - Swiss drugmaker Novartis on Thursday defeated a bid to invalidate its patent for blockbuster heart drug Entresto, with London's High Court rejecting a claim by Intas Pharmaceuticals' Accord Healthcare which was planning a generic rival. The ruling is a boost for Novartis as it navigates a busy period of patent expiries including for Entresto, which makes up about 10% of Novartis' sales. Novartis' European patent for Entresto, which treats heart failure and can also treat hypertension, expired in 2023 though it still has a so-called supplementary protection certificate which does not expire until 2028. Accord applied to the High Court for a ruling that Novartis' patent had always been invalid, while Novartis counterclaimed over the threatened infringement of its patent, with Accord intending to launch a competing product later this year. Judge Richard Meade said that "all the attacks on the patent fail". He ruled that Novartis' patent was valid while in force, its supplementary protection certificate was also valid and that Accord's intended product would infringe it. Novartis and Accord did not immediately respond to requests for comment. Meade also said that Novartis' patent was separately held to be valid after legal proceedings in the Netherlands. The company last year lost a bid in the United States to block a generic version of Entresto. (Reporting by Sam Tobin; Editing by Susan Fenton)
Blood pressure drug recalled nationwide, FDA announces. Kristine Gasbarre Qaderi Tue, August 11, 2026 at 4:02 AM PDT * Novartis voluntarily recalls its brand-name blood pressure drug Diovan due to quality flaw related to drug dissolution specifications. When a prescription drug is recalled, often it's a generic version that's being pulled from market. But this time, it's a name-brand blood pressure drug by a pharmaceutical company with its own recognizable name. In a report sent out Saturday, August 8, the U.S. Food and Drug Administration (FDA) announced that Novartis had voluntarily initiated an August 4 recall on Diovan, the company's brand of valsartan, which the Mayo Clinic explains is an angiotensin II receptor blocker, "blocking a substance in the body that causes blood vessels to tighten." The Mayo Clinic adds: "Valsartan is used alone or together with other medicines to treat high blood pressure (hypertension)... Valsartan is also used to treat heart failure and left ventricular failure after a heart attack." The FDA report states that the recall is due to "Failed Dissolution Specifications," a quality flaw which could possibly mean that testing revealed the drug doesn't dissolve as indicated for bodily absorption. How to tell if your prescription is affected. The FDA provided the following details in its report: * Diovan (valsartan) 160 mg (milligrams) * 90 tablets, Rx only * Lot: AV5913C * Expiration: 06/2027 * Quantity: not available The drug was reportedly manufactured by North Carolina-based Patheon Manufacturing Services and distributed by Norvartis's New Jersey office. What's the overall risk? The FDA was quick to determine a risk level for the Diovan recall, naming it a Class II event on Friday, August 7. This is the FDA's mid-tier severity level, which they define as "a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote."